Evaluation of Strontium-۸۹ in palliative treatment of widespread and painful bone metastases due to breast and prostate cancer [Persian]
- سال انتشار: 1379
- محل انتشار: مجله پزشکی هسته ای ایران، دوره: 8، شماره: 1
- کد COI اختصاصی: JR_IRJNM-8-1_010
- زبان مقاله: انگلیسی
- تعداد مشاهده: 140
نویسندگان
Department of Radiation Oncology, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran
Department of Radiation Oncology, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran
Department of Radiation Oncology, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran
Department of Biostatistics, Faculty of Health, Tehran University of Medical Sciences, Tehran, Iran
چکیده
Treatment of bone metastases comprises over ۱۰% of the workload of a radiation-oncology center. Bone metastases produce severe pain and immobility, necessitate narcotic use, and reduce the quality of life. A good palliative treatment must be complete, free from side effects and fast; Thus we decided to evaluate Strontium-۸۹ (۸۹Sr) effectivity for palliation of breast and prostate cancer bone metastases in relation to above factors. The use of ۸۹Sr radionuclide therapy started on ۱۹۹۲ in radiation-oncology department of Cancer Institute. Until early ۱۹۹۹, ۹۱ patients with bone metstases have been treated for pain relief in our department with ۴ mCi of ۸۹Sr. Of these, ۸۰ were breast and prostate metastatic cancers. ۳۵ patients came back for follow-up and were completely evaluated. Response was seen in ۶۵% of patients (Complete response in ۴۰% and partial response in ۲۵%). Side effects were negligible, and quality of life of the responding patients significantly increased. There was no significant relationship between the type of primary cancer or patient age and response. In conclusion, treatment of metastatic bone cancer from prostate and breast primaries in our department was effective, with a relatively high rate of response and no serious side effects.کلیدواژه ها
Bone Metastases, Radionuclide therapy, Strontium-۸۹, Radiotherapy, Breast cancer, prostate cancerاطلاعات بیشتر در مورد COI
COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.
کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.